PedAM
Pediatric Disease Annotations & Medicines
| Disease | basal cell carcinoma |
| Phenotype | C0004779|basal cell nevus syndrome |
| Sentences | 3 |
| PubMedID- 21668511 | Conclusion: methylaminolevulinate-photodynamic therapy seems an interesting option for the treatment of basal cell carcinomas in patients with basal cell nevus syndrome. |
| PubMedID- 25386306 | It is also required to bring the hair follicle from the resting to the growth phase.4 loss of heterozygosity and inactivation mutations in ptch1 and smo have been implicated in the development of the majority of basal cell carcinomas (bccs)5–7 and in patients with basal cell nevus syndrome (bcns).7,8 vismodegib (gdc-0449) is a synthetic small molecule inhibitor of smo that blocks downstream hhsp target genes; it has favorable pharmaceutical properties and greater potency than cyclopamine.9,10 a phase i dose-finding, safety, and tolerability study of vismodegib in patients with advanced bcc and solid tumors was conducted, demonstrating primarily mild to moderate side effects.6,7 here we report on our experience of treating two patients with advanced bcc participating in the phase i study6,7 who have received ongoing daily treatment for 2.75–>3 years without experiencing any significant side effects that might be anticipated with chronic hhsp inhibition. |
| PubMedID- 24212808 | At the present moment a randomized phase ii trial to determine the effectiveness of celecoxib in preventing basal cell carcinoma in patients with basal cell nevus syndrome has been completed and a trial on the use of celecoxib in preventing skin cancer in patients with actinic keratosis is still ongoing. |
Page: 1